Researchers at Michigan Medicine report a potential new therapeutic target for gastrointestinal neuroendocrine tumors: a ...

The tumor begins before birth. Somewhere in the developing fetus, neural crest cells that should have matured into adrenal tissue or sympathetic ganglia take a wrong turn, and a child is born ...

Neuroendocrine cells are unique in their ability to act both as nerve cells and hormone-making cells. They're scattered ...

Neuroendocrine cells are unique in their ability to act both as nerve cells and hormone-making cells.They're scattered throughout the body, including ...

MTX240 is a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction ...

BDRX READ THE FULL BDRX RESEARCH REPORT We are initiating coverage of Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) with a valuation of $7.00. Biodexa is a clinical-stage GI oncology company focused on ...

As has been the case for the past few years, financing for small- and micro-cap biotech companies remains challenging. The ...

Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company’s lead development ...

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

March 23, 2026Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma ...

Celcuity highlighted strong phase III second-line data for gedatolisib in PIK3CA "wild-type" HR-positive breast cancer — the triplet (gedatolisib + palbociclib + fulvestrant) showed median PFS of 9.3 ...